Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04432857
Title AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adlai Nortye Biopharma Co., Ltd.
Indications

triple-receptor negative breast cancer

lung squamous cell carcinoma

bladder urothelial carcinoma

colorectal cancer

cervical cancer

lung non-squamous non-small cell carcinoma

Therapies

E7046 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | FRA

Facility Status City State Zip Country Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
University of Utah School of Medicine Huntsman Cancer Institute Recruiting Salt Lake City Utah 84112 United States Details
University of Virginia Recruiting Richmond Virginia 22908 United States Details
Centre Léon Bérard Recruiting Lyon France Details
Gustave Roussy Recruiting Paris 94805 France Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field